Jazz: New HER2-Positive Biliary Tract Cancer Data at ASCO 2024

 Zanidatamab demonstrated a median overall survival (OS) of 15.5 months in patients with centrally confirmed immunohistochemistry (IHC) 2+ or 3+ and a median OS of 18.1 months in patients with IHC 3+ tumors

With approximately two years of median follow-up, as of July 28, 2023, median duration of response (DOR) increased by two months from initial analysis to 14.9 months

https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-presents-overall-survival-and-longer-follow-up-data-from-herizon-btc-01-trial-evaluating-zanidatamab-in-previously-treated-her2-positive-biliary-tract-cancer-at-asco-2024-302161115.html